Pharmacogenetic CYP2D6 variability, phenoconversion and treatment outcomes: A Danish population-based cohort study in 6,798 individuals initiating atomoxetine treatment

Pharmacogenetic CYP2D6 variability, phenoconversion and treatment outcomes: A Danish population-based cohort study in 6,798 individuals initiating atomoxetine treatment

Introduction Atomoxetine, a first-line treatment option for ADHD, is affected by pharmacogenetic (PGx) variation of the drug-metabolizing enzyme CYP2D6. Despite the recommendation of CYP2D6 testing, the use of PGx-guided dosing remains low in Denmark. Objectives We investigated wide-ranging clinic...

Full description

Bibliographic Details
Main Authors: K. Ishtiak-Ahmed, C. Lunenburg, J. Thirstrup, L. Clausen, P. Thomsen, C. Gasse
Format: Article
Language:English
Published: Cambridge University Press 2022-06-01
Series:European Psychiatry
Subjects:
treatment switching
CYP2D6 inhibitors
adhd
sleeping problem
Online Access:https://www.cambridge.org/core/product/identifier/S0924933822005880/type/journal_article

Internet

https://www.cambridge.org/core/product/identifier/S0924933822005880/type/journal_article

Similar Items